DDInter1432 DDInter927
An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Perphenazine {u} (Compound) resembles {v} (Compound) Triflupromazine
Perphenazine {u} (Compound) resembles {v} (Compound) Propericiazine
Perphenazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cetirizine
Perphenazine {u} (Compound) binds {v} (Gene) CYP2C18
Perphenazine {u} (Compound) upregulates {v} (Gene) ST3GAL5
Perphenazine {u} (Compound) palliates {v} (Disease) Gilles de la Tourette syndrome
Perphenazine {u} (Compound) is included by {v} (Pharmacologic Class) Phenothiazines
Perphenazine {u} (Compound) downregulates {v} (Gene) TXNDC9
Perphenazine {u} (Compound) causes {v} (Side Effect) Nocturnal confusion
Perphenazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sucralfate
Perphenazine (Compound) resembles Triflupromazine (Compound)
Perphenazine (Compound) resembles Propericiazine (Compound)
Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine
Perphenazine (Compound) binds CYP2C18 (Gene)
Perphenazine (Compound) upregulates ST3GAL5 (Gene)
Perphenazine (Compound) palliates Gilles de la Tourette syndrome (Disease)
Perphenazine (Compound) is included by Phenothiazines (Pharmacologic Class)
Perphenazine (Compound) downregulates TXNDC9 (Gene)
Perphenazine (Compound) causes Nocturnal confusion (Side Effect)
Perphenazine may cause a minor interaction that can limit clinical effects when taken with Sucralfate